Form D · Other
Endogena Therapeutics, Inc.
San Francisco, CA · CIK 0001838748
Offering snapshot reported Nov 19, 2021 · SEC filing
- Reported sold
- $7.35M Offering amount: $25M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 19, 2021 | Initial | $7,346,961 | No comparison | 12 | SEC filing |
| Jan 5, 2021 | Initial | $7,999,924 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-421883
Source: Form D, filed Nov 19, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Elona Baum | Director |
| Markus Bertini | Executive |
| Dirk Harbecke | Director |
| Matthias Steger | Director, Executive |
| Aaron Weaver | Director |
| Daniel Zabrowski | Director |
Issuer details
Industry: Other (See others in industry)
Address:
111 Pine Street Suite 1410
San Francisco, CA, 94111
San Francisco, CA, 94111